LATEST GUIDELINES ON GROWTH HORMONE DEFICIENCY (GHD) AND IDIOPATHIC SHORT STATURE (ISS)/GROWTH HORMONE THERAPY IN TURNER SYNDROME

Speciality: Pediatrics

Description:

A warm welcome to all the medical professionals in this interesting session on the Latest Guidelines on Growth Hormone Deficiency (GHD) and Idiopathic Short Stature (ISS)/Growth Hormone Therapy in Turner Syndrome.
The latest guidelines for Growth Hormone Deficiency (GHD) emphasize individualized treatment approaches. The Endocrine Society recommends initiating recombinant human growth hormone (rhGH) therapy for children

diagnosed with GHD, with the primary goal of achieving normal growth velocity and reaching a height within the individual's genetic potential. Treatment should be monitored regularly with adjustments made based on growth response and insulin-like growth factor 1 (IGF-1) levels to ensure safety and efficacy. Regular follow-up visits are crucial for monitoring potential side effects and optimizing long-term outcomes for patients​

Recent guidelines for treating Idiopathic Short Stature (ISS) from the Pediatric Endocrine Society recommend growth hormone therapy in specific cases where children exhibit significantly short stature (height more than 2.25 standard deviations below the mean) and poor growth velocity. The decision to start treatment should weigh the psychosocial impacts of short stature against the benefits and risks of therapy. 

Therefore, get an overall knowledge of latest guidelines on growth hormone deficiency (GHD) and idiopathic short stature (ISS)/growth hormone therapy in turner syndrome.
 

See More Webinars @ Hidoc Webinars